Comprehensive Technical Guidance for CTD Modules 1–5

1. INTRODUCTION

Granulation in Pharma Manufacturing
Granulation in Pharma Manufacturing

The registration of pharmaceutical products in Chile is overseen by the Instituto de Salud Pública de Chile (ISP) under the Ministry of Health. Pharmaceutical dossiers must be submitted in CTD format (Modules 1–5) and comply with Decreto Supremo 3/2010, Good Manufacturing Practices (GMP), therapeutic equivalence rules, and ISP’s electronic submission system.

All documents must be in PDF format, clearly bookmarked, searchable, and the total file must not exceed 10 MB per upload.

MODULE 1 – ADMINISTRATIVE & FUNCTIONAL INFORMATION

This module contains country-specific administrative requirements. It is not harmonized globally and must follow Chilean (ISP) regulations precisely.

1.1 Administrative & Legal Module

1.1.1 Module 1 Table of Contents

Provide a complete TOC covering all administrative elements.

1.1.2 Cover Letter

Must include:

  • Product name (INN & brand)
  • Dosage form, strength, route
  • Manufacturer details (API and FPP)
  • Purpose (new registration / renewal / variation)
  • List of uploaded documents
  • Declaration of completeness and accuracy

1.2 Specific Information under National Regulation

1.2.1 Application Form (Formulario de Solicitud ISP)

Mandatory fields:

  • Holder information (local representative required)
  • Manufacturing sites (API / FPP / packers)
  • Commercial presentations
  • Therapeutic equivalence (bioequivalence) category
  • Controlled substance classification (if applicable)

1.2.2 Request Letter for Undisclosed Information

For confidential manufacturing processes & proprietary knowledge.

1.2.3 Changes of Health Registration Holder

Required only for ownership transfers.

1.2.4 Agreements & Legal Support Documentation

1.2.4.1 Manufacturing & Distribution Chain Diagram

Shows complete supply chain: API → FPP → packing → shipping → Chile importer → distributor.

1.2.4.2 GMP Certificates (Mandatory)

Both API & Finished Product GMP certificates must be attached.
Requirements:

  • Must be issued by competent authority
  • Must confirm compliance with pharmaceutical GMP
  • Valid and recent (not older than 3 years)
  • Must be legalized/apostilled as required by ISP
1.2.4.2.1 Active Ingredient GMP Certificate

From API manufacturer’s national authority.

1.2.4.2.2 Finished Product GMP Certificate

From FPP manufacturer’s authority (for Taj Pharma: WHO-GMP, PIC/S, or country authority).

1.2.4.3 Product Certificate (CPP/CFS)

Certificate of Pharmaceutical Product (WHO format) or Certificate of Free Sale.

1.2.4.4 Manufacturing Agreement

Contract between MAH and manufacturer.

1.2.4.5 Quality Control Agreement

Defines responsibility for final QC release.

1.2.4.6 Import Agreement

Required when Chilean importer handles local logistics.

1.2.4.7 Storage & Distribution Agreement

Temperature control and GDP compliance required.

1.2.4.8 Local Conditioning Agreement

If labeling/packaging is performed in Chile.

1.2.4.9 Power of Attorney

Authorizing local representative.

1.3 Medication Information & Labeling

1.3.1 Professional Information Brochure (PPI)

Chile-specific SmPC equivalent.

1.3.2 Patient Information Brochure (PIL)

Spanish language mandatory.

1.3.3 Labeling & Model Design

Must comply with Decreto 3/2010:

  • Legible Spanish text
  • Storage conditions
  • Lot & expiry format
  • Special risk labeling

1.3.4 Finished Product Specifications

Release and shelf-life specification summary.

1.4 Specific Requirements for Special Applications

1.4.1 Literature-based Applications

For well-established substances.

1.4.2 Justification of New Fixed-dose Combinations

1.4.3 Certificates of Suitability (CEP)

For APIs covered under EDQM monographs.

1.5 Pharmacovigilance Information

1.5.1 Pharmacovigilance System Master File (PSMF)

Chile must have a local QPPV.

1.5.2 Risk Management Plan (RMP)

ICH E2E format.

1.5.3 Pharmacovigilance System Agreement (NVS)

1.6 Biopharmaceutical Studies

1.6.1 Bioavailability/Bioequivalence Identification

Include BE protocol, comparator, site accreditation.

1.6.2 Bioexemption Justification (BCS Class I/III)

Chile accepts BCS-based waivers for eligible APIs.

1.6.3 Alternative Therapeutic Equivalence Methods

In vitro dissolution, IVIVC, comparative QC.

1.7 Validation of Production Process

1.7.1 Process Validation Forms

Three consecutive commercial batches validation.

1.7.2 Post-validation Modifications

1.8 Pediatric Product Information

1.8.1 Pediatric Development Program

1.8.2 Ethanol Use Justification

1.9 Foreign Regulatory Information

Includes:

  • Approval letters abroad
  • Dossiers comparison
  • Evaluation reports (if available)
  • WHO PQ certificate

1.10 Meetings / Consultations with ISP

Attach minutes if applicable.

1.11 Product Change History

Track all historical variations.

MODULE 2 – GENERAL SUMMARY (CTD SUMMARIES)

Contains expert-written overviews and summaries.

2.1 Module 2 Table of Contents

2.2 CTD Introduction

Explain product, origin, manufacturing sites, and global regulatory status.

QUALITY OVERVIEW

2.3.S Active Ingredient (API)

2.3.S.1 General Information

  • INN, CAS
  • Physicochemical properties
  • Polymorphism

2.3.S.2 Manufacturing Process

  • Flow diagram
  • Controls
  • Solvents/reagents

2.3.S.3 Characterization

  • Structure elucidation
  • Impurity profile

2.3.S.4 API Controls

  • Specifications (ICH Q6A/Q6B)
  • Analytical methods
  • Validation
  • Batch COAs

2.3.S.5 Reference Standards

2.3.S.6 Container Closure

2.3.S.7 Stability

Long-term + accelerated data according to ICH.

2.3.P Finished Pharmaceutical Product (FPP)

2.3.P.1 Composition

2.3.P.2 Pharmaceutical Development

  • Formulation rationale
  • Excipient compatibility
  • Dissolution profile
  • Container selection

2.3.P.3 Manufacturing Process

  • Master formula
  • Batch size
  • In-process controls
  • CPP identification

2.3.P.4 Excipient Control

2.3.P.5 Finished Product Specifications

  • Release tests
  • Stability tests
  • Impurities

2.3.P.6 Reference Standards

2.3.P.7 Container System

2.3.P.8 Stability Summary

2.4 Non-clinical Overview

Summaries of pharmacology, pharmacokinetics, and toxicology.

2.5 Clinical Overview

Includes rationale, clinical pharmacology, efficacy, safety, and risk-benefit.

2.6 Non-clinical Written & Tabulated Summaries

2.7 Clinical Summary

Including BE summaries, efficacy and safety summaries.

MODULE 3 – QUALITY (FULL DATA)

This is the most critical module for generics.

3.1 Module 3 Table of Contents

3.2.S Active Ingredient (Full Information)

3.2.S.1 General Information

  • Nomenclature (INN, CAS)
  • Structural formula
  • Physicochemical characterization

3.2.S.2 Manufacturing Process

Must include:

  • Complete API manufacturer details
  • Flow chart + control points
  • Detailed process description
  • Regulated solvents and impurity control
  • CPP or CEP if applicable

3.2.S.3 Characterization

Comprehensive:

  • NMR, IR, MS
  • Polymorph and solvates
  • Impurities (related & residual)

3.2.S.4 Controls

  • Microbial limits
  • Specification justification
  • Reference standards

3.2.S.5 Reference Standards

3.2.S.6 Container Closure System

3.2.S.7 Stability

Must follow:

  • ICH Q1A(R2)
  • Data supporting shelf-life and storage for Chile (climates III/IV)

3.2.P Finished Pharmaceutical Product

3.2.P.1 Description & Composition

3.2.P.2 Pharmaceutical Development

Provide detailed:

  • Excipient compatibility
  • Dissolution development
  • Manufacturing optimization
  • Critical parameters
  • Microbiological considerations

3.2.P.3 Manufacturing Process

Include:

  • Batch manufacturing records
  • Granulation, compression, coating parameters
  • Environmental controls
  • Equipment lists

3.2.P.4 Excipients

  • Specifications
  • Origin check for animal-derived excipients

3.2.P.5 Control of FPP

  • Analytical validation
  • Dissolution method
  • Impurity limits
  • Batch results for 3 lots

3.2.P.6 Reference Standards

3.2.P.7 Container-Closure System

  • Packaging material specifications
  • Extractable/leachable data (if applicable)

3.2.P.8 Stability

  • Real-time & accelerated
  • Photostability (if required)
  • Post-approval stability commitment

MODULE 4 – NON-CLINICAL INFORMATION

Generally applicable for:

  • New drugs
  • New combinations
  • APIs without prior approval

For generics, non-clinical may be minimal.

4.1 Table of Contents

4.2 Study Reports

4.2.1 Pharmacology

  • Primary effects
  • Secondary effects
  • Safety pharmacology

4.2.2 Pharmacokinetics

  • Absorption, distribution, metabolism, excretion
  • Analytical method validation

4.2.3 Toxicology

  • Acute & repeated dose
  • Reproductive toxicity
  • Genotoxicity
  • Carcinogenicity

4.3 Bibliographic References

MODULE 5 – CLINICAL INFORMATION

Mandatory for:

  • Generics: Bioequivalence studies or BCS-based waiver
  • New molecules: complete clinical package

5.1 Table of Contents

5.2 Tabulation of All Clinical Studies

5.3 Clinical Study Reports

5.3.1 Biopharmaceutical Studies

  • BE study reports (with Chile-acceptable comparator)
  • Bioanalytical method validation
  • IVIVC if required

5.3.2 PK Studies using Human Biomaterials

5.3.3 Clinical Pharmacokinetic Reports

5.3.4 Pharmacodynamics (PD) Studies

5.3.5 Safety & Efficacy Reports

Only needed for:

  • New drugs
  • New indications
  • Complex generics

5.3.6 Post-marketing Experience

5.3.7 Case Report Forms

5.4 Bibliographic References

KEY REGULATORY SUCCESS FACTORS FOR CHILE

✔ Complete, searchable, high-quality PDFs

✔ Apostilled/legalized GMP Certificates (API + FPP)

✔ Strong pharmaceutical development (Module 3)

✔ Valid bioequivalence or BCS exemption justification

✔ Clear labeling following Chilean norms

✔ Regulatory chain-of-custody documentation

✔ Active coordination with Chilean local representative

This guidance ensures Taj Pharma submits a fully compliant CTD dossier tailored to Chile’s ISP requirements.

Quality Assurance (QA) Team Ensures Uncompromised Compliance With International GMP Standards

Taj Pharma is globally recognized for its stringent adherence to Good Manufacturing Practices (GMP) and its commitment to delivering safe, effective, and reliable pharmaceutical products across international markets. One of the strongest pillars of this reputation is the company’s robust Quality Assurance (QA) system, which aligns seamlessly with global regulatory requirements, including those mandated by authorities such as the Cambodia Ministry of Health (MOH).

This article explores, in depth, how Taj Pharma’s QA team ensures compliance, maintains product integrity, and supports international registration and approval processes—including the regulatory expectations of Cambodia MOH.

1. The Role of QA in Global Regulatory Compliance

Taj Pharma’s QA division operates as the custodian of compliance, ensuring all products meet:

  • WHO-GMP
  • PIC/S cGMP Guidelines
  • ISO 9001:2018 Quality Management Systems
  • Cambodia MOH Drug Registration Standards
  • ASEAN Common Technical Dossier (ACTD) guidelines

The QA team’s responsibility is not limited to quality checks; it includes strategic alignment with global pharmaceutical norms, product lifecycle oversight, and complete documentation management to meet varying international regulatory expectations.

2. QA Oversight in Cambodia MOH Compliance

To achieve product registration approval from the Cambodia MOH, Taj Pharma ensures:

✔ Fully Compliant ACTD Dossiers

QA collaborates with Regulatory Affairs to prepare:

  • Product Formulation Data
  • Stability Studies (Zone IVb conditions: 30°C/75% RH)
  • Manufacturing Process Validation
  • Batch Manufacturing Records (BMR)
  • Batch Packaging Records (BPR)
  • Quality Analytical Validation

The QA team ensures that every document meets Cambodia MOH’s Department of Drugs and Food (DDF) standards.

✔ GMP Conformance Letters & Plant Certifications

All Taj Pharma facilities maintain internationally inspected:

  • WHO-GMP Certificates
  • ISO 9001:2018 Certification
  • PIC/S aligned manufacturing systems
  • Up-to-date Site Master Files (SMF)

QA ensures the availability and accuracy of these documents during dossier submission.

✔ Product Quality Review (PQR) for MOH Audits

Annual PQRs are prepared in line with ASEAN regulatory expectations, ensuring:

  • Consistency between batches
  • Review of deviations
  • Trend analysis of stability results
  • Review of complaints and market feedback

3. End-to-End QA System at Taj Pharma

3.1 Raw Material Qualification

  • All raw materials undergo strict vendor qualification.
  • QA verifies Certificate of Analysis (CoA) and performs full incoming tests.
  • Materials failing quality parameters are immediately quarantined and rejected.

3.2 In-Process Quality Control (IPQC)

IPQC checkpoints monitored by QA include:

  • Granulation parameters
  • Blend uniformity
  • Tablet/pellet weight variation
  • Hardness, friability, and disintegration
  • Capsule fill weight consistency

Each step is validated to ensure batch uniformity consistent with global regulatory guidelines.

3.3 Process Validation (PV)

Taj Pharma performs:

  • Prospective Validation
  • Concurrent Validation
  • Re-validation (post any major change)

PV ensures that the manufacturing process consistently produces products of expected quality.

4. Documentation: The Heart of QA Compliance

Taj Pharma strictly follows ALCOA+ principles:

  • Attributable
  • Legible
  • Contemporaneous
  • Original
  • Accurate
  • **+**Complete, Consistent, Enduring, Available

The QA team oversees controlled documentation systems, including:

  • SOPs
  • Validation Protocols
  • Change Control Records
  • Deviation Reports
  • CAPA Records
  • Training Logs
  • Equipment Calibration Records

This ensures traceability and audit readiness for global authorities, including MOH Cambodia.

5. QA Assurance in Finished Product Quality

Final batch release is managed exclusively by QA based on:

  • Analytical test results
  • Microbial testing
  • Stability data
  • Packaging integrity checks
  • Label conformity

No product is released without QA authorization, ensuring compliance with the marketing authorization dossier submitted to foreign regulatory bodies.

6. Compliance Through Training & Competency Building

Taj Pharma’s QA department organizes:

  • GMP Training Programs
  • Mock Audits
  • Regulatory Updates Sessions
  • Data Integrity Workshops

All employees are trained to maintain compliance with:

  • WHO Standards
  • Cambodia MOH Requirements
  • ASEAN GMP
  • PIC/S regulations

7. Internal and External Audits

Internal Audits

Conducted quarterly to verify:

  • Adherence to SOPs
  • Cleanroom practices
  • Batch record accuracy
  • Calibration & maintenance logs
  • Validation status

External Audits

Taj Pharma is inspected by:

  • Foreign Regulatory Authorities
  • WHO/ISO Certification Bodies
  • Partner Auditors
  • Clients from ASEAN, Africa, Middle East, CIS, LATAM

QA ensures regulatory compliance by preparing sites for successful inspections, including those required by Cambodia MOH for product approval.

8. Stability Studies for ASEAN Region

Taj Pharma performs ICH stability studies under:

  • Accelerated
  • Intermediate
  • Long-term (Zone IVb) conditions

Stability results are incorporated into:

  • Product dossiers
  • PQR reports
  • Regulatory submissions

Ensuring the products remain stable in hot/humid climates such as Cambodia.

9. Post-Marketing Surveillance (PMS)

Taj Pharma’s QA department oversees:

  • Adverse Drug Reaction (ADR) tracking
  • Market complaint handling
  • Product recall procedures
  • Continuous improvement programs

This strengthens the company’s credibility with regulatory authorities worldwide.

Taj Pharma’s Quality Assurance system is designed to meet the rigorous expectations of global regulatory agencies—including the Cambodia Ministry of Health (MOH). By maintaining strict GMP compliance, robust documentation systems, validated manufacturing practices, and transparent quality controls, Taj Pharma ensures that every product destined for the Cambodian market and beyond is safe, effective, and reliable.

The QA team’s dedication to excellence positions Taj Pharma as a trusted international manufacturer, reinforcing its leadership in global pharmaceutical exports and regulatory compliance.